

NEWS RELEASE

RECORDATI: REGISTRATION WITH THE COMPANIES' REGISTER OF THE RESOLUTION APPROVING THE CROSS BORDER MERGER OF THE SUBSIDIARY RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY IN RECORDATI S.p.A.

Milan, April 7, 2017 – Following the press release dated April 5, 2017, Recordati S.p.A. informs that, today, the Board of Directors resolution approving the cross border merger by absorption by Recordati S.p.A. of the Luxembourg company Recordati S.A. Chemical and Pharmaceutical Company, entirely held by the former, was registered with Companies' Register of Milan.

The aforementioned resolution is available to the public at the Company's registered office and published on the Company's website (<u>www.recordati.it</u>; Section Corporate Governance, Other Corporate Documents) and on the authorized storage mechanism managed by Computershare S.p.A. (<u>www.linfo.it</u>).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America, in Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2016 was \in 1,153.9 million, operating income was \in 327.4 million and net income was \in 237.4 million.

For further information:

Recordati website: <u>www.recordati.com</u>

Investor Relations Marianne Tatschke (39)0248787393 e-mail: <u>inver@recordati.it</u> <u>Media Relations</u> Studio Noris Morano (39)0276004736, (39)0276004745 e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

CAPITALE SOCIALE € 26.140.644,50 I.V. REG. IMP. MILANO N. 00748210150 CODICE FISCALE/P.IVA 007482210150 R.E.A. MILANO N. 401832